MAPT and Alzheimer disease: Furthermore, trajectory modeling strategies can be applied to longitudinal data of other AD biomarkers such as tau PET, plasma or cerebrospinal fluid measures of Aβ/tau, and cognitive data to further characterize the natural history of AD progression.